Robert Bosch Venture Capital joins Variantyx's US $26 million Series C funding round
Summary
Variantyx provides clinicians with advanced diagnostics and personalized treatment recommendations for oncology patients based on their unique genetic makeup. We are pleased to partner with Variantyx, utilizing their unique proprietary software to analyze data more precisely to create a more insightful approach to cancer therapy," says Helia Schönthaler, COO of Robert Bosch Medical Research. It uses its expertise in sensor technology, software, and services, as well as its own IoT cloud, to offer its customers connected, cross-domain solutions from a single source. The Bosch Groups strategic objective is to facilitate connected living with products and solutions that either contain artificial intelligence (AI) or have been developed or manufactured with its help. The platform delves deep into the genetics of an individual, providing insights and analytics that no other diagnostic test can deliver today and in the shortest amount of time.